oral glp-1 drugs GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies Oral GLP-1 Orforglipron Is Approved

With the participation of researchers from the Paul Langerhans Institute Dresden (PLID), partner at the German Center for Diabetes Research, a GLP-1 receptor agonist in the form of tablets could for the first time be compared with the most common second-line therapy of T2D, a DPP-IV inhibitor

Originally developed and positioned as treatments for type 2 diabetes, these agents are now equally associated with weight management, reshaping how clinicians, patients, and pharmacies understand metabolic disease

Gastric ultrasound identifies increased residual gastric contents in patients on GLP-1 receptor agonists, showing that shorter drug withholding and fasting times are linked to higher aspiration risk before anesthesia.

Case reports document perioperative aspiration in semaglutide users, including episodes of hypoxemia and reintubation despite guideline-concordant fasting

This article explores the science behind these agents.

This formula is designed to naturally enhance your bodys GLP-1 hormone productiona key factor in